Biotech RadarJobs updated

COMPANY

Amylyx Pharmaceuticals

HQ: Cambridge, MA source · amylyx.com ↗ · New England

Clinical Phase 3

44 open jobs · last seen Oct 23, 2026 · 13 sources

AMX0114 is an Amylyx-developed, intrathecally administered antisense oligonucleotide (ASO) designed to target calpain-2, a protein involved in axonal degeneration and neurofilament biology. From company website Source · Oct 12, 2026

Keywords: oligonucleotide antisense Amyotrophic Lateral Sclerosis Post Bariatric Hypoglycemia Neurodegenerative Diseases Progressive Supranuclear Palsy PSP Atypical Parkinsonism Wolfram Syndrome Alzheimer Disease Motor Neuron Disease Neuromuscular Diseases Spinal Cord Diseases TDP-43 Proteinopathies Nervous System Diseases Central Nervous System Diseases AMX0035 Avexitide

Profile checked Oct 10, 2026

44Open jobs$235.0MRaised (2 yrs)13Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Associate Director, IT Commercial and Medical Affairs ApplicationsCambridge, MAOct 16, 2026Oct 17, 2026
Manager, HR OperationsCambridge, MAOct 16, 2026Oct 17, 2026
Director, Regional Access TeamCambridge, MAOct 13, 2026Oct 15, 2026
Regional Sales Director, West RegionUS - WestOct 9, 2026Oct 12, 2026
Regional Sales Director, Southwest RegionUS - SouthwestOct 9, 2026Oct 12, 2026

See all 44 jobs

Timeline

  1. Raise Follow-on offering: $175M (total, as published), announced Sep 10, 2025. Source: company's own press page. source ↗
  2. Trial start Phase 3: Avexitide for Treatment of Post-Bariatric Hypoglycemia source ↗
  3. Trial start Phase 1: AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis source ↗
  4. Raise Follow-on offering: $60M (total, as published), announced Jan 10, 2025. Source: company's own press page. source ↗
  5. Trial start Phase 2/Phase 3: AMX0035 and Progressive Supranuclear Palsy source ↗
  6. Trial start Phase 2: AMX0035 in Adult Patients With Wolfram Syndrome source ↗
  7. Trial start Phase 3: Extension Study Evaluating The Safety And Tolerability of AMX0035 source ↗
  8. Trial start III: Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment source ↗
  9. Trial start Phase 1/Phase 2: Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS source ↗
  10. Trial start Phase 2/Phase 3: A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS) source ↗
  11. Trial start Phase 2: Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease source ↗
  12. Trial start Phase 2: Open Label Extension Study of AMX0035 in Patients With ALS source ↗
  13. Trial start Phase 2: AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS) source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $235.0M. Last 2 years.

Clinical trials (lead sponsor) 13

RecordTitlePhaseStatusStartPrimary completion
NCT06747468Avexitide for Treatment of Post-Bariatric HypoglycemiaPhase 3Active, not recruitingApr 29, 2025Jul 8, 2026 (actual)
NCT07582874An Expanded Access Protocol to Provide Avexitide in Patients With Post-Bariatric HypoglycemiaNot listedAvailableNot listedNot listed
NCT06122662AMX0035 and Progressive Supranuclear PalsyPhase 2/Phase 3CompletedDec 21, 2023Sep 30, 2025 (actual)
NCT05676034AMX0035 in Adult Patients With Wolfram SyndromePhase 2Active, not recruitingMar 3, 2023Jul 23, 2024 (actual)
NCT06665165AMX0114 in Adult Participants With Amyotrophic Lateral SclerosisPhase 1RecruitingApr 7, 20252027-02 (estimated)
NCT03488524Open Label Extension Study of AMX0035 in Patients With ALSPhase 2CompletedMar 29, 2018Mar 1, 2021 (actual)
NCT03533257Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's DiseasePhase 2CompletedSep 14, 2018Oct 22, 2020 (actual)
NCT05619783Extension Study Evaluating The Safety And Tolerability of AMX0035Phase 3CompletedDec 29, 2022Oct 16, 2024 (actual)
NCT05021536Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis TreatmentIIIUnknown status (ClinicalTrials.gov)Oct 28, 2021Jan 19, 2024 (actual)
NCT03127514AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)Phase 2CompletedJun 22, 2017Sep 25, 2019 (actual)
NCT04987671Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALSPhase 1/Phase 2Unknown status (ClinicalTrials.gov)Aug 5, 2021May 11, 2022 (actual)
NCT04516096A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)Phase 2/Phase 3CompletedNov 22, 2020Dec 30, 2022 (actual)
NCT05286372An Intermediate Size Expanded Access Protocol of AMX0035 for ALSNot listedApproved for marketingNot listedNot listed

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Open jobs 44

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Associate Director, IT Commercial and Medical Affairs ApplicationsCambridge, MAOct 16, 2026Oct 17, 2026Not stated
Manager, HR OperationsCambridge, MAOct 16, 2026Oct 17, 2026Not stated
Director, Regional Access TeamCambridge, MAOct 13, 2026Oct 15, 2026Senior
Regional Sales Director, West RegionUS - WestOct 9, 2026Oct 12, 2026Senior
Regional Sales Director, Southwest RegionUS - SouthwestOct 9, 2026Oct 12, 2026Senior
Regional Sales Director, Central RegionUS - CentralOct 9, 2026Oct 12, 2026Senior
Regional Sales Director, Southeast RegionUS - SoutheastOct 9, 2026Oct 12, 2026Senior
Regional Sales Director, Mid-South RegionUS - Mid-SouthOct 9, 2026Oct 12, 2026Senior
Regional Sales Director, Mid-Atlantic RegionUS - Mid-AtlanticOct 9, 2026Oct 12, 2026Senior
Regional Sales Director, Midwest RegionUS - MidwestOct 9, 2026Oct 12, 2026Senior
Senior Director, PharmacometricsCambridge, MAOct 8, 2026Oct 12, 2026Senior
Director, Clinical Business OperationsCambridge, MAOct 7, 2026Oct 12, 2026Senior
Associate Director, Commercial Training and DevelopmentCambridge, MAOct 7, 2026Oct 12, 2026Senior
Director of Sales Effectiveness and OperationsCambridge, MAOct 6, 2026Oct 12, 2026Senior
Regional Sales Director, New England RegionUS - New EnglandOct 6, 2026Oct 12, 2026Senior
Senior Director, New Product PlanningCambridge, MAOct 6, 2026Oct 12, 2026Senior
Director, Clinical OperationsCambridge, MAOct 5, 2026Oct 12, 2026Senior
Manager, Quality Control and Analytical DevelopmentCambridge, MAOct 5, 2026Oct 12, 2026Mid
Associate Director, Commercial Quality ControlCambridge, MAOct 5, 2026Oct 12, 2026Senior
Executive Assistant, CommercialCambridge, MAOct 2, 2026Oct 12, 2026Senior
Senior Process Engineer, MSAT, Drug SubstanceCambridge, MAOct 2, 2026Oct 12, 2026Senior
Consultant, Director of Patient MarketingCambridge, MAOct 2, 2026Oct 12, 2026Senior
Director, Manufacturing Sciences and Technology (MSAT)Cambridge, MAOct 2, 2026Oct 12, 2026Senior
Senior Director, Clinical SystemsCambridge, MAOct 1, 2026Oct 12, 2026Senior
Senior Manager, AnalyticsCambridge, MASep 30, 2026Oct 12, 2026Senior
Vice President, Clinical Compliance and SystemsCambridge, MASep 28, 2026Oct 12, 2026Executive
Associate Director, Incentive Compensation and Field ReportingCambridge, MASep 24, 2026Oct 12, 2026Senior
Senior Director, Avexitide Brand LeadCambridge, MASep 22, 2026Oct 12, 2026Senior
Associate Director, Pricing and Access AnalyticsCambridge, MASep 18, 2026Oct 12, 2026Senior
Director, Access MarketingCambridge, MASep 18, 2026Oct 12, 2026Senior
Associate Director, Data ArchitectCambridge, MASep 15, 2026Oct 12, 2026Senior
Senior Director, Safety PhysicianCambridge, MASep 10, 2026Oct 12, 2026Senior
Executive AssistantCambridge, MASep 8, 2026Oct 12, 2026Senior
Senior Manager, Corporate CommunicationsCambridge, MASep 8, 2026Oct 12, 2026Senior
Vice President, Legal OperationsCambridge, MASep 4, 2026Oct 12, 2026Executive
Manager, IT Commercial and Medical Affairs ApplicationsCambridge, MAAug 28, 2026Oct 12, 2026Mid
Senior Director, Clinical PharmacologyCambridge, MA - RemoteAug 7, 2026Oct 23, 2026Not stated
Director, FP&A - CommercialCambridge, MAJul 30, 2026Oct 12, 2026Senior
Accounts Payable SpecialistCambridge, MAJul 28, 2026Oct 12, 2026Entry
Senior Director, ToxicologyCambridge, MAJul 9, 2026Oct 12, 2026Senior
Associate Director, Clinical Compliance & RecordsCambridge, MAJul 1, 2026Oct 12, 2026Senior
Director, Clinical SciencesCambridge, MAMay 27, 2026Oct 12, 2026Senior
Associate Director, Clinical Data ProgrammerCambridge, MAMar 5, 2026Oct 12, 2026Senior
Senior Medical Director, Clinical DevelopmentCambridge, MAJul 29, 2025Oct 12, 2026Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Connect

See your connections at Amylyx Pharmaceuticals on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback